Loading…
Immuneering Corporation is projected to rise to $6.03 by 2027, a +18% move from its current price of $5.11. IMRX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $4.92 | $5.11 | $5.31 | +0.01% |
| Jul 15 | $4.84 | $5.11 | $5.40 | +0.02% |
| Jul 16 | $4.78 | $5.11 | $5.46 | +0.02% |
| Jul 17 | $4.73 | $5.11 | $5.52 | +0.03% |
| Jul 18 | $4.69 | $5.11 | $5.57 | +0.04% |
| Jul 19 | $4.65 | $5.11 | $5.62 | +0.05% |
| Jul 20 | $4.62 | $5.11 | $5.66 | +0.06% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $4.62 | $5.11 | $5.66 | +0.06% |
| Week 2 | $4.43 | $5.12 | $5.91 | +0.11% |
| Week 3 | $4.29 | $5.12 | $6.10 | +0.17% |
| Week 4 | $4.18 | $5.12 | $6.28 | +0.23% |
| Week 5 | $4.08 | $5.12 | $6.43 | +0.28% |
| Week 6 | $4.00 | $5.13 | $6.58 | +0.34% |
| Week 7 | $3.92 | $5.13 | $6.71 | +0.40% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Immuneering Corporation is a late-stage oncology company that develops medicines for broad populations of cancer patients in the United States.
Key programs include IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF, and IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for solid tumors.
The company has clinical supply agreements with Regeneron Pharmaceuticals to evaluate atebimetinib in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer; and with Eli Lilly and Company to evaluate atebimetinib in combination with olomorasib in patients with advanced or metastatic KRAS G12C-mutant non-small cell lung cancer. Immuneering was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Immuneering Corporation (IMRX) is a healthcare stock with a current price of $5.19.
Its market capitalization is $335.78M and it ranks 3311.
The near-term technical picture is bullish, with RSI(14) at 60, SMA50 at $4.93, and SMA200 at $5.69; there is a defined support at $3.92 and resistance at $5.77.
The 30-day range runs from $4.02 to $6.70, and annualized volatility is 70%.
A major floor 39.7% below — a decisive break under it would weaken the trend.
The nearest floor, 23.3% below — buyers have tended to step in here.
The nearest ceiling, 12.9% above — a clean break opens room to run.
A major ceiling 32.7% above — clearing it would confirm fresh momentum.
Key IMRX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of IMRX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $5.25 | Sell | $5.21 | Sell |
| MA 10 | $5.13 | Sell | $5.09 | Buy |
| MA 20 | $4.74 | Buy | $4.92 | Buy |
| MA 50 | $4.88 | Buy | $4.92 | Buy |
| MA 100 | $5.09 | Buy | $5.06 | Buy |
| MA 200 | $5.61 | Sell | $5.03 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 55.18 | Neutral |
| Stoch RSI (14) | 42.42 | Neutral |
| CCI (20) | 63.57 | Neutral |
| Williams %R (14) | -38.53 | Info |
| MACD (12,26,9) | 0.09 | Buy |
| ROC (12) | 12.56 | Buy |
| Bollinger %B (20,2) | 0.71 | Neutral |
| Stochastic %K (14) | 61.47 | Neutral |
| TRIX (15) | 0.17 | Buy |
| Awesome (5,34) | 0.52 | Buy |
| Ultimate (7,14,28) | 57.16 | Neutral |
| Momentum (10) | 0.58 | Buy |
| Aroon Osc (25) | 72.00 | Buy |
| Hull MA (9) | 5.38 | Sell |
| ADX (14) | 16.52 | Neutral |
| ATR (14) | 0.17 | Info |
The 30-day technical picture shows a bullish tilt, supported by an RSI of 60 and price action trading above the SMA50 of $4.93 while staying near the SMA200 of $5.69.
Key levels to watch are support at $3.92 and resistance at $5.77, with the 30-day range between $4.02 and $6.70.
The current momentum sits within a volatile environment, as indicated by an annualized volatility of 70%, which can contribute to quick moves around the nearby support and resistance.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.92 | $5.11 | $7.12 | 0% | Neutral | |
| $4.62 | $6.03 | $8.42 | +18% | Neutral | |
| $5.65 | $7.69 | $11.29 | +50% | Bullish | |
| $5.85 | $8.24 | $12.56 | +61% | Bullish | |
| $7.62 | $11.06 | $17.41 | +116% | Bullish | |
| $10.22 | $15.26 | $24.68 | +199% | Bullish | |
| $10.18 | $15.61 | $25.88 | +205% | Bullish | |
| $10.56 | $16.61 | $28.16 | +225% | Bullish | |
| $11.19 | $18.02 | $31.18 | +253% | Bullish | |
| $11.36 | $18.74 | $33.02 | +267% | Bullish | |
| $18.98 | $34.88 | $66.45 | +583% | Bullish | |
| $39.96 | $88.81 | $189.02 | +16.4x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $3.92 | $5.11 | $6.37 | +0.00% |
| August 2026 | $4.45 | $5.31 | $6.54 | +3.82% |
| September 2026 | $4.27 | $5.15 | $6.45 | -2.97% |
| October 2026 | $4.35 | $5.28 | $6.70 | +2.63% |
| November 2026 | $4.51 | $5.52 | $7.08 | +4.52% |
| December 2026 | $4.46 | $5.50 | $7.12 | -0.43% |
Click any year to see its month-by-month IMRX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, IMRX is projected to trade between $3.92 and $7.12, averaging $5.11 — a potential gain of 0% from today's $5.11. A consolidation phase looks the most probable path here.
Immuneering Corporation's 2027 outlook centres on $6.03, within a $4.62 to $8.42 range. That is up +18% on the projected 2026 average. That marks a +18% change versus current levels. Price action looks broadly range-bound.
By 2028, IMRX could reach as high as $11.29, with a base case around $7.69 and support toward $5.65 — roughly +50% from $5.11. Buyers look set to stay in control over this stretch.
Expect IMRX to range from $5.85 to $12.56 through 2029. The $8.24 average target implies a +61% move from current prices. That is up +7% on the projected 2028 average. Momentum favours further upside here.
The IMRX price prediction for 2030 points to an average of $11.06 (low $7.62, high $17.41) — a potential gain of +116% on today's $5.11. Buyers look set to stay in control over this stretch.
In 2031, IMRX is projected to trade between $10.22 and $24.68, averaging $15.26 — a potential gain of +199% from today's $5.11. That is up +38% on the projected 2030 average. Momentum favours further upside here.
Immuneering Corporation's 2032 outlook centres on $15.61, within a $10.18 to $25.88 range. That is up +2% on the projected 2031 average. That marks a +205% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, IMRX could reach as high as $28.16, with a base case around $16.61 and support toward $10.56 — roughly +225% from $5.11. Momentum favours further upside here.
Expect IMRX to range from $11.19 to $31.18 through 2034. The $18.02 average target implies a +253% move from current prices. That is up +8% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The IMRX price prediction for 2035 points to an average of $18.74 (low $11.36, high $33.02) — a potential gain of +267% on today's $5.11. Momentum favours further upside here.
In 2040, IMRX is projected to trade between $18.98 and $66.45, averaging $34.88 — a potential gain of +583% from today's $5.11. That is up +86% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Immuneering Corporation's 2050 outlook centres on $88.81, within a $39.96 to $189.02 range. That is up +155% on the projected 2040 average. That marks a +16.4x change versus current levels. Momentum favours further upside here.
Investing $1,000 in IMRX today (≈ 195.694716 IMRX) could be worth
$17,379.06
+$16,379.06 (+1638%) by 2050 · US Dollar
Based on the average projected IMRX price of $88.81 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in IMRXwould be worth at today's price.
$1,000 invested in IMRX on Jul 10, 2025 (≈ 230.946886 IMRX) would be worth
$1,180.14
+$180.14 (+18.0%) today · 1.18× · US Dollar
Based on a IMRX entry price of $4.33 vs. today's $5.11.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $5.19 | $984.59 | -1.5% |
| 1 month ago | $3.92 | $1,303.57 | +30.4% |
| 3 months ago | $5.52 | $925.72 | -7.4% |
| 6 months ago | $4.22 | $1,210.9 | +21.1% |
| 1 year ago | $4.33 | $1,180.14 | +18.0% |
| All time (4.9y) ago | $17.59 | $290.51 | -70.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our IMRX forecast.
Our base-case forecast reaches $10.00 around 2030.
Implied market cap at $10.00: $646.97M
The multi-year forecast shows substantial upside across the horizon. The 2026 forecast lists an average price of $5.19 with a neutral sentiment, while 2027 shows an avg of $6.20 (ROI 19.5) and neutral sentiment. The forecast then turns bullish from 2028 onward, with 2028 avg $7.77 (ROI 49.7), 2029 avg $8.23 (ROI 58.6), and 2030 avg $11.32 (ROI 118.2).
Beyond 2030, the projections continue to rise with 2031 avg $15.48 (ROI 198.3), 2032 avg $15.52 (ROI 199.1), 2033 avg $16.77 (ROI 223.1), 2034 avg $18.20 (ROI 250.6), and 2035 avg $18.62 (ROI 258.7), all labeled bullish.
Longer-horizon forecasts show very strong upside: 2040 avg $34.73 (ROI 569.3) and 2050 avg $88.27 (ROI 1600.7), both with bullish sentiment. These figures are estimates and not guarantees, reflecting potential paths for price and return over time.
Tap a question to reveal the answer.
2030 min: $7.78; avg: $11.32; max: $17.86; roiPct: 118.2; sentiment: BULLISH.
Forecasts show NEUTRAL sentiment in 2026 and 2027, turning BULLISH from 2028 onward. 2027 avg $6.20 (ROI 19.5); 2028 avg $7.77 (ROI 49.7); 2029 avg $8.23 (ROI 58.6); 2030 avg $11.32 (ROI 118.2); 2040 avg $34.73 (ROI 569.3); 2050 avg $88.27 (ROI 1600.7). These are estimates and not guarantees.
2034 max: $31.55; avg: $18.20; min: $11.26; roiPct: 250.6; sentiment: BULLISH. This indicates a path that could exceed $20 by 2034 in the max forecast.
2027 min: $4.74; avg: $6.20; max: $8.69; roiPct: 19.5; sentiment: NEUTRAL.
2040 min: $18.83; avg: $34.73; max: $66.33; roiPct: 569.3; sentiment: BULLISH.
Immuneering Corporation Community Discussion
0Share your Immuneering Corporation price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.